SUBSCRIBE: Print / eNewsletter
Partial Breast Irradiation Sufficient in Early Disease
Accelerated partial breast irradiation was shown to be just as effective and safe as whole breast irradiation in early-stage breast cancer patients.
Preventive Tamoxifen Lowers Rate of ER-Positive Breast Cancer
Tamoxifen given to women at high risk for breast cancer lowered the rate of estrogen receptor (ER)-positive breast cancer diagnosis in the IBIS-I trial.
Fulvestrant Improved Survival in First-Line Advanced Breast Cancer
Fulvestrant improved overall survival compared with anastrozole, among women with treatment-naive, advanced, hormone receptor-positive breast cancer.
Decreased Fat Intake May Improve Survival in Some Breast Cancers
Data from the Women’s Intervention Nutrition Study found a reduction in dietary fat intake resulted in lower death rates in ER- and PR-negative breast cancer.
Avastin May Benefit Basal-Like Breast Cancer Patients
A study of triple-negative breast cancer patients found that adding bevacizumab to chemo resulted in higher pCR rates in those with basal-like disease.
Ovarian Suppression Benefits Young Breast Cancer Patients
Early-stage premenopausal ER-positive breast cancer patients who have received chemotherapy benefited from ovarian suppression with tamoxifen or exemestane.
Capecitabine Ineffective in Elderly Early Breast Cancer Patients
The use of adjuvant capecitabine in elderly patients with moderate- to high-risk early breast cancer resulted in no improvement in disease-free survival.
Immunotherapy Yields Response in Triple-Negative Breast Cancer
The PD-1 inhibitor pembrolizumab showed activity and had an acceptable safety profile in heavily pretreated metastatic triple-negative breast cancer patients.
PI3K Inhibitor in ER-Positive Breast Cancer Shows Activity
Results of a phase II study of a PI3K inhibitor in ER-positive breast cancer showed a trend toward improved progression-free survival.
Marker in HER2-Positive Breast Cancer Linked to Chemo Benefit
The level of stromal tumor-infiltrating lymphocytes (Str-TILs) may influence which treatment is the most effective in women with HER2-positive breast cancer.